AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd (ASTRAZEN) last traded at ₹7,130, a market capitalisation of ₹17,825 crore, on a P/E of 103. Over the past 52 weeks the stock has ranged between ₹7,120 and ₹9,850. AstraZeneca Pharma India Ltd last reported results for the quarter ended Jun 2026, with sales of ₹683 crore and net profit of ₹38 crore. The next scheduled event is an analyst meet on 26 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
AstraZeneca Pharma India Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
AstraZeneca Pharma India Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹683 cr, up 29.8% from ₹526 cr a year earlier. Net profit was ₹38 cr, down 32.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 408 | 440 | 480 | 526 | 559 | 612 | 579 | 683 |
| Expenses | 355 | 363 | 394 | 445 | 484 | 567 | 518 | 634 |
| Operating profit | 53 | 77 | 86 | 81 | 75 | 45 | 61 | 49 |
| OPM % | 13% | 17% | 18% | 15% | 13% | 7% | 11% | 7% |
| Other income | 8 | -26 | 10 | 11 | 1 | 7 | 5 | 9 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 9 | 9 | 18 | 17 | 3 | 4 | 6 | 5 |
| Profit before tax | 51 | 42 | 78 | 75 | 73 | 47 | 58 | 51 |
| Tax % | 25% | 27% | 26% | 25% | 26% | 30% | 23% | 25% |
| Net profit | 38 | 31 | 58 | 56 | 54 | 33 | 45 | 38 |
| EPS (₹) | 15.37 | 12.34 | 23.30 | 22.33 | 21.69 | 13.04 | 17.95 | 15.17 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
AstraZeneca Pharma India Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 814 | 806 | 1,003 | 1,296 | 1,716 | 2,276 | 2,432 |
| Operating profit | 135 | 86 | 165 | 184 | 254 | 262 | 230 |
| OPM % | 17% | 11% | 16% | 14% | 15% | 12% | 9% |
| Net profit | 93 | 62 | 99 | 162 | 116 | 188 | 170 |
| EPS (₹) | 37.32 | 24.64 | 39.72 | 64.60 | 46.30 | 75.01 | 67.85 |
TTM is the trailing twelve months to the most recent quarter.
AstraZeneca Pharma India Ltd growth and returns
- 10 Years
- 15%
- 5 Years
- 23%
- 3 Years
- 31%
- TTM
- 31%
- 10 Years
- 43%
- 5 Years
- 16%
- 3 Years
- 15%
- TTM
- -18%
- 10 Years
- 21%
- 5 Years
- 19%
- 3 Years
- 20%
- 1 Year
- -13%
- 10 Years
- 21%
- 5 Years
- 22%
- 3 Years
- 23%
- Last Year
- 23%
AstraZeneca Pharma India Ltd shareholding pattern
Promoters held 75.00% at Jun 2026, broadly unchanged since Jun 2025. FIIs 2.68% and DIIs 6.08%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FIIs | 2.90% | 2.92% | 2.89% | 3.03% | 2.74% | 2.71% | 2.78% | 2.68% |
| DIIs | 5.08% | 5.21% | 4.65% | 4.55% | 5.26% | 5.55% | 5.79% | 6.08% |
| Public | 17.02% | 16.85% | 17.45% | 17.41% | 17.00% | 16.73% | 16.42% | 16.24% |
| No. of shareholders | 27,615 | 27,322 | 32,466 | 34,378 | 32,914 | 31,551 | 29,007 | 29,338 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming AstraZeneca Pharma India Ltd events
The next scheduled event is an analyst meet on 26 Aug 2026.
- Analyst meetOne-on-one meeting with institutional investor
See the full results calendar for every Indian company reporting in the next 30 days.
AstraZeneca Pharma India Ltd corporate filings
- Please find the enclosed intimation of the Company in relation to the captioned subject for reference.Company Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Ltd has submitted a disclosure regarding its ESG rating in…
Read the full analysis - Please find the enclosed intimation of the Company in relation to the captioned subject for your reference.Company Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Ltd has filed a routine intimation regarding an upcoming analyst…
Read the full analysis - Please find the enclosed intimation of the Company as per the captioned subject for your reference.Company Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Ltd has filed an intimation regarding an upcoming…
Read the full analysis - Please find the enclosed intimation of the Company as per the captioned subject for your reference.AGM/EGMlow impact
Cruxal's analysis: AstraZeneca Pharma India Limited has successfully concluded its 47th Annual General…
Read the full analysis - Please find the enclosed Press Release of the Company for your reference.Company Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Ltd has filed a press release under Regulation 30 of the SEBI…
Read the full analysis - Please find the enclosed intimation of the Company as per the captioned subject for your reference.AGM/EGMlow impact
Cruxal's analysis: AstraZeneca Pharma India Limited has successfully concluded its 47th Annual General…
Read the full analysis - Please find the enclosed intimation of the Company as per the captioned subject for your reference.Resulthigh impact
Cruxal's analysis: AstraZeneca Pharma India Limited delivered a robust performance for the quarter ended…
Read the full analysis - Please find the enclosed letter of the Company as per the captioned subject for your reference.Company Updatelow impact
Cruxal's analysis: AstraZeneca Pharma India Ltd has submitted a routine disclosure under Regulation 30 of…
Read the full analysis - Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve This is to inform ....Board Meetinglow impact
Cruxal's analysis: AstraZeneca Pharma India Limited has announced that its Board of Directors will convene…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track AstraZeneca Pharma India Ltd
Cruxal reads every AstraZeneca Pharma India Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.